Suggestions
Adam Koppel
Partner, Bain Capital Life Sciences
Adam Koppel is a prominent figure in the healthcare and investment sectors, currently serving as a Managing Director at Bain Capital Life Sciences. Here's a comprehensive overview of his background and career:
Education and Early Career
Adam Koppel holds an impressive academic background. He graduated magna cum laude from Harvard University with bachelor's and master's degrees in history and science.1 He then went on to earn an M.D. and Ph.D. in neuroscience from the University of Pennsylvania School of Medicine, as well as an M.B.A. from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar.15
Professional Experience
Bain Capital: Koppel's career at Bain Capital has been extensive and multifaceted:
- He initially joined Bain Capital Public Equity in 2003, where he was a leader in the healthcare sector until 2014.12
- In 2016, he rejoined Bain Capital as Managing Director of the Bain Capital Life Sciences Fund, a position he currently holds.23
Biogen: Between his stints at Bain Capital, Koppel served as Executive Vice President of Corporate Development and Chief Strategy Officer at Biogen from 2014 to 2016.23
McKinsey & Company: Prior to his initial role at Bain Capital, Koppel was an Associate Principal at McKinsey & Company in New Jersey, where he worked with various healthcare companies.14
Board Memberships
Koppel serves on the board of directors for several companies, including:
- Solid Biosciences, Inc.
- Dicerna Pharmaceuticals, Inc.
- Aptinyx Inc.
- Foghorn Therapeutics, Inc.
- Cerevel Therapeutics135
He has also previously served on the boards of Trevena, Inc. and PTC Therapeutics, Inc.1
Other Affiliations
Koppel is involved in various healthcare and community organizations:
- Newton-Wellesley Hospital Board of Trustees
- Partners Healthcare Innovation Advisory Board
- Society for Neuroscience Investment Committee
- Boston Museum of Science Board of Trustees5
Adam Koppel's extensive experience in healthcare, finance, and strategy, combined with his strong academic background, has established him as a respected leader in the life sciences investment sector.
